Ontology type: schema:ScholarlyArticle Open Access: True
2021-03-11
AUTHORSJerald P. Radich, Andreas Hochhaus, Tamás Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez Casares, J. Valentín García-Gutiérrez, Eibhlin Conneally, Philipp D. le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saussele, Francis J. Giles, David M. Ross, Paola Aimone, Sai Li, Ksenia Titorenko, Giuseppe Saglio
ABSTRACTThe ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are presented herein. Patients who had received ≥2 years of frontline nilotinib therapy and achieved MR4.5 underwent a 1-year nilotinib treatment consolidation phase before attempting TFR. At the 5-year data cut-off, 81/190 patients entering the TFR phase (42.6%) were still in TFR, with 76 (40.0%) in MR4.5. Patients who lost major molecular response (MMR) entered a treatment re-initiation phase; 90/91 patients entering this phase (98.9%) regained MMR and 84/91 patients (92.3%) regained MR4.5. The Kaplan–Meier estimated treatment-free survival rate at 5 years was 48.2%. No disease progression or CML-related deaths were reported. Whereas the incidence of adverse events (AEs) declined from 96 weeks following the start of TFR, an increase in AE frequency was observed for patients in the treatment re-initiation phase. Low Sokal risk score, BCR-ABL1IS levels at 48 weeks of TFR and stable MR4.5 response for the first year of TFR were associated with higher TFR rates. Overall, these results support the efficacy and safety of attempting TFR following upfront nilotinib therapy of >3 years in patients with CML-CP. More... »
PAGES1344-1355
http://scigraph.springernature.com/pub.10.1038/s41375-021-01205-5
DOIhttp://dx.doi.org/10.1038/s41375-021-01205-5
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1136297746
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/33707652
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Kaplan-Meier Estimate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myeloid, Chronic-Phase",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein Kinase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrimidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Rate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA",
"id": "http://www.grid.ac/institutes/grid.270240.3",
"name": [
"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
],
"type": "Organization"
},
"familyName": "Radich",
"givenName": "Jerald P.",
"id": "sg:person.011362420057.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Abteilung H\u00e4matologie/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany",
"id": "http://www.grid.ac/institutes/grid.275559.9",
"name": [
"Abteilung H\u00e4matologie/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany"
],
"type": "Organization"
},
"familyName": "Hochhaus",
"givenName": "Andreas",
"id": "sg:person.01064615503.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Semmelweis University, Budapest, Hungary",
"id": "http://www.grid.ac/institutes/grid.11804.3c",
"name": [
"Semmelweis University, Budapest, Hungary"
],
"type": "Organization"
},
"familyName": "Masszi",
"givenName": "Tam\u00e1s",
"id": "sg:person.0751651512.21",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751651512.21"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical University of Gda\u0144sk, Gda\u0144sk, Poland",
"id": "http://www.grid.ac/institutes/grid.11451.30",
"name": [
"Medical University of Gda\u0144sk, Gda\u0144sk, Poland"
],
"type": "Organization"
},
"familyName": "Hellmann",
"givenName": "Andrzej",
"id": "sg:person.01154416326.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154416326.31"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Aarhus University Hospital, Aarhus, Denmark",
"id": "http://www.grid.ac/institutes/grid.154185.c",
"name": [
"Aarhus University Hospital, Aarhus, Denmark"
],
"type": "Organization"
},
"familyName": "Stentoft",
"givenName": "Jesper",
"id": "sg:person.016036621425.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016036621425.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain",
"id": "http://www.grid.ac/institutes/grid.411250.3",
"name": [
"Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain"
],
"type": "Organization"
},
"familyName": "Casares",
"givenName": "Mar\u00eda Teresa G\u00f3mez",
"id": "sg:person.013411572177.22",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013411572177.22"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain",
"id": "http://www.grid.ac/institutes/grid.411347.4",
"name": [
"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain"
],
"type": "Organization"
},
"familyName": "Garc\u00eda-Guti\u00e9rrez",
"givenName": "J. Valent\u00edn",
"id": "sg:person.01203162637.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203162637.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "St James\u2019s Hospital, Dublin, Ireland",
"id": "http://www.grid.ac/institutes/grid.416409.e",
"name": [
"St James\u2019s Hospital, Dublin, Ireland"
],
"type": "Organization"
},
"familyName": "Conneally",
"givenName": "Eibhlin",
"id": "sg:person.01132647406.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132647406.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany",
"id": "http://www.grid.ac/institutes/grid.6363.0",
"name": [
"Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "le Coutre",
"givenName": "Philipp D.",
"id": "sg:person.01344447222.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.14778.3d",
"name": [
"Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "Norbert",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy",
"id": "http://www.grid.ac/institutes/grid.414504.0",
"name": [
"Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy"
],
"type": "Organization"
},
"familyName": "Martino",
"givenName": "Bruno",
"id": "sg:person.01105522434.09",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105522434.09"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany",
"id": "http://www.grid.ac/institutes/grid.7700.0",
"name": [
"III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany"
],
"type": "Organization"
},
"familyName": "Saussele",
"givenName": "Susanne",
"id": "sg:person.0611020122.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611020122.69"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Developmental Therapeutics Consortium, Chicago, IL, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Developmental Therapeutics Consortium, Chicago, IL, USA"
],
"type": "Organization"
},
"familyName": "Giles",
"givenName": "Francis J.",
"id": "sg:person.011165370517.24",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011165370517.24"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Haematology, SA Pathology, Royal Adelaide Hospital, Adelaide, Australia",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Division of Haematology, SA Pathology, Royal Adelaide Hospital, Adelaide, Australia"
],
"type": "Organization"
},
"familyName": "Ross",
"givenName": "David M.",
"id": "sg:person.01110323637.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110323637.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharma AG, Basel, Switzerland",
"id": "http://www.grid.ac/institutes/grid.419481.1",
"name": [
"Novartis Pharma AG, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Aimone",
"givenName": "Paola",
"id": "sg:person.01156721025.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156721025.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharma AG, Basel, Switzerland",
"id": "http://www.grid.ac/institutes/grid.419481.1",
"name": [
"Novartis Pharma AG, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Li",
"givenName": "Sai",
"id": "sg:person.013222113051.10",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013222113051.10"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharmaceuticals Corporation, Moscow, Russian Federation",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Novartis Pharmaceuticals Corporation, Moscow, Russian Federation"
],
"type": "Organization"
},
"familyName": "Titorenko",
"givenName": "Ksenia",
"id": "sg:person.011367550003.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011367550003.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Turin, Orbassano, Italy",
"id": "http://www.grid.ac/institutes/grid.7605.4",
"name": [
"University of Turin, Orbassano, Italy"
],
"type": "Organization"
},
"familyName": "Saglio",
"givenName": "Giuseppe",
"id": "sg:person.01334477453.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00432-018-2604-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1101145018",
"https://doi.org/10.1007/s00432-018-2604-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2017.63",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083850241",
"https://doi.org/10.1038/leu.2017.63"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2016.104",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047140338",
"https://doi.org/10.1038/leu.2016.104"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41375-020-0776-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1125320161",
"https://doi.org/10.1038/s41375-020-0776-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41375-020-01111-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1134383975",
"https://doi.org/10.1038/s41375-020-01111-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2016.5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041273297",
"https://doi.org/10.1038/leu.2016.5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2016.115",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022073613",
"https://doi.org/10.1038/leu.2016.115"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2017.253",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1091207323",
"https://doi.org/10.1038/leu.2017.253"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-03-11",
"datePublishedReg": "2021-03-11",
"description": "The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are presented herein. Patients who had received \u22652 years of frontline nilotinib therapy and achieved MR4.5 underwent a 1-year nilotinib treatment consolidation phase before attempting TFR. At the 5-year data cut-off, 81/190 patients entering the TFR phase (42.6%) were still in TFR, with 76 (40.0%) in MR4.5. Patients who lost major molecular response (MMR) entered a treatment re-initiation phase; 90/91 patients entering this phase (98.9%) regained MMR and 84/91 patients (92.3%) regained MR4.5. The Kaplan\u2013Meier estimated treatment-free survival rate at 5 years was 48.2%. No disease progression or CML-related deaths were reported. Whereas the incidence of adverse events (AEs) declined from 96 weeks following the start of TFR, an increase in AE frequency was observed for patients in the treatment re-initiation phase. Low Sokal risk score, BCR-ABL1IS levels at 48 weeks of TFR and stable MR4.5 response for the first year of TFR were associated with higher TFR rates. Overall, these results support the efficacy and safety of attempting TFR following upfront nilotinib therapy of >3 years in patients with CML-CP.",
"genre": "article",
"id": "sg:pub.10.1038/s41375-021-01205-5",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1097065",
"issn": [
"0887-6924",
"1476-5551"
],
"name": "Leukemia",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "35"
}
],
"keywords": [
"treatment-free remission",
"major molecular response",
"chronic myeloid leukemia",
"adverse events",
"nilotinib therapy",
"myeloid leukemia",
"chronic phase chronic myeloid leukemia",
"treatment-free survival rate",
"phase chronic myeloid leukemia",
"CML-related deaths",
"Sokal risk score",
"higher TFR rates",
"long-term outcomes",
"TFR phase",
"TFR rate",
"frontline nilotinib",
"CML-CP",
"nilotinib treatment",
"chronic phase",
"Kaplan-Meier",
"disease progression",
"risk score",
"patients",
"survival rate",
"data cut",
"MR4.5",
"remission",
"therapy",
"leukemia",
"AE frequency",
"first year",
"trials",
"consolidation phase",
"weeks",
"molecular response",
"years",
"nilotinib",
"incidence",
"progression",
"response",
"death",
"efficacy",
"outcomes",
"treatment",
"scores",
"rate",
"safety",
"levels",
"start",
"update",
"events",
"increase",
"results",
"frequency",
"feasibility",
"phase",
"cut"
],
"name": "Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial",
"pagination": "1344-1355",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1136297746"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/s41375-021-01205-5"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"33707652"
]
}
],
"sameAs": [
"https://doi.org/10.1038/s41375-021-01205-5",
"https://app.dimensions.ai/details/publication/pub.1136297746"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:11",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_900.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/s41375-021-01205-5"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41375-021-01205-5'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41375-021-01205-5'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41375-021-01205-5'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41375-021-01205-5'
This table displays all metadata directly associated to this object as RDF triples.
359 TRIPLES
21 PREDICATES
101 URIs
85 LITERALS
18 BLANK NODES